Intervention

Bempegaldesleukin

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 2 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials2

Recruiting0

Common conditions3

Lead sponsors shown2

Clinical trials

2 shown

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid TumorsNCT04052204 · 2019-12-30

TERMINATED

A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic CancerNCT03548467 · 2018-04-04

COMPLETED

Common conditions

Locally Advanced or Metastatic Solid Tumours1 Metastatic Castration Resistant Prostate Cancer (mCRPC)1 Squamous Cell Carcinoma of the Head and Neck (SCCHN)1

Leading sponsors

Nykode Therapeutics ASA1 Pfizer1

Trial status mix

COMPLETED1

TERMINATED1

Phase mix

PHASE12

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.